Skip to main content
2026 CRT Conference Main banner

Ryan J. Tedford, MD

Chief, Heart Failure; Peter C. Gazes Chair in Heart Failure
Medical University of South Carolina, South Carolina, United States

Dr. Tedford is a Professor of Medicine/Cardiology and holds the Dr. Peter C. Gazes Endowed Chair in Heart Failure at the Medical University of South Carolina (MUSC) in Charleston, SC. He currently serves as the section head of heart failure and medical director of cardiac transplantation. He also established and directs the Advanced Heart Failure and Transplant Fellowship Program at MUSC. He is currently a Dr. Tedford is an internationally recognized clinical researcher and has published over 300 peer-reviewed original research manuscripts, invited expert reviews, editorials and book chapters. His research efforts are focused on hemodynamic assessment of right ventricle function and its interaction with the pulmonary circulation and left heart. He was the co-chair of the PH due to left heart disease task force for 7th World Symposium on Pulmonary Hypertension. He is currently a deputy editor for Circulation.

Disclosure(s): 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Presentation(s):

Email Ryan